Drug Profile
Desmopressin buccal - Catalent
Alternative Names: Desmopressin buccal tabletLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Columbia Laboratories
- Developer Catalent
- Class Antidiuretics; Antihaemorrhagics; Hormones; Peptides; Urologics; Vasoconstrictors; Vasopressins
- Mechanism of Action Vasopressin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Enuresis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Enuresis in USA (Buccal, Tablet)
- 13 Apr 2015 Columbia Laboratories is now called Juniper Pharmaceuticals
- 19 Aug 2009 Columbia Laboratories is in discussions with a potential partner for the development of desmopressin buccal